PARP1 and neoplasm: Furthermore, the use of PARP inhibitors can be extended to tumor cells without BRCA mutations because most solid tumors contain hypoxic cells.122 Similarly, through further study of conditional SL, other internal conditions such as proteotoxic stress and metabolic stress may be proven to increase the range of synthetic lethal interactions.123